+Compare
ATNM
Stock ticker: ASE
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
166.31M

ATNM Actinium Pharmaceuticals Forecast, Technical & Fundamental Analysis

a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ATNM with price predictions
08:00 PM EDT Sep 28, 2023

ATNM in -4.21% downward trend, falling for three consecutive days on September 29, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ATNM declined for three days, in of 361 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ATNM moved out of overbought territory on September 12, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on September 18, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on ATNM as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ATNM turned negative on September 20, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

ATNM moved below its 50-day moving average on September 13, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ATNM crossed bearishly below the 50-day moving average on September 18, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

ATNM broke above its upper Bollinger Band on September 11, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 93 cases where ATNM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ATNM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.144) is normal, around the industry mean (22.693). P/E Ratio (0.000) is within average values for comparable stocks, (131.605). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.099). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. ATNM's P/S Ratio (3333.333) is very high in comparison to the industry average of (304.777).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 402 to 410.54B. NVO holds the highest valuation in this group at 410.54B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 23%, and the average quarterly price growth was 42%. CRIS experienced the highest price growth at 1,363%, while BCLI experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was 41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

ATNM is expected to report earnings to fall 6.71% to -54 cents per share on October 27

Actinium Pharmaceuticals ATNM Stock Earnings Reports
Q3'23
Est.
$-0.54
Q2'23
Missed
by $0.02
Q1'23
Missed
by $0.01
Q4'22
Missed
by $0.01
Q3'22
Missed
by $0.03
The last earnings report on July 31 showed earnings per share of -57 cents, missing the estimate of -56 cents. With 222.03K shares outstanding, the current market capitalization sits at 166.31M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
275 Madison Avenue
Phone
+1 646 677-3870
Employees
49
Web
https://www.actiniumpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TMCTX45.42-0.06
-0.13%
Touchstone Mid Cap Z
SBIIX9.14-0.04
-0.44%
Sterling Capital Behavioral Intl Eq Inst
FIDLX40.53-0.18
-0.44%
Fidelity Advisor® Large Cap Z
SSCYX5.25-0.04
-0.76%
Saratoga Small Capitalization A
FNCRX28.76-0.43
-1.47%
Franklin Natural Resources C

ATNM and

Correlation & Price change

A.I.dvisor tells us that ATNM and GRTS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ATNM and GRTS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATNM
1D Price
Change %
ATNM100%
-3.90%
GRTS - ATNM
33%
Poorly correlated
+10.26%
MRNS - ATNM
32%
Poorly correlated
-2.06%
ORMP - ATNM
31%
Poorly correlated
+3.98%
ASND - ATNM
31%
Poorly correlated
-1.38%
ALNY - ATNM
31%
Poorly correlated
+1.76%
More

Groups containing ATNM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATNM
1D Price
Change %
ATNM100%
-3.90%
cancer
(undefined stocks)
36%
Loosely correlated
-0.33%
drugs
(undefined stocks)
35%
Loosely correlated
+5.05%
biopharmaceuticals
(undefined stocks)
35%
Loosely correlated
-0.46%
biotechnology
(undefined stocks)
34%
Loosely correlated
+5.41%
immunotherapy
(undefined stocks)
21%
Poorly correlated
+0.53%